123 related articles for article (PubMed ID: 8323274)
1. Specificity mapping of HIV-1 protease by reduced bond inhibitors.
Majer P; Urban J; Gregorová E; Konvalinka J; Novek P; Stehlíková J; Andreánsky M; Sedlácek J; Strop P
Arch Biochem Biophys; 1993 Jul; 304(1):1-8. PubMed ID: 8323274
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptidemimetics.
Ghosh AK; McKee SP; Sanders WM; Darke PL; Zugay JA; Emini EA; Schleif WA; Quintero JC; Huff JR; Anderson PS
Drug Des Discov; 1993; 10(1):77-88. PubMed ID: 8399995
[TBL] [Abstract][Full Text] [Related]
3. Development of pseudopeptide inhibitors of HIV-1 aspartic protease: analysis and tuning of the subsite specificity.
Tossi A; Antcheva N; Romeo D; Miertus S
Pept Res; 1995; 8(6):328-34. PubMed ID: 8838416
[TBL] [Abstract][Full Text] [Related]
4. On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
Dusková J; Dohnálek J; Skálová T; Petroková H; Vondrácková E; Hradílek M; Konvalinka J; Soucek M; Brynda J; Fábry M; Sedlácek J; Hasek J
Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):489-97. PubMed ID: 16627941
[TBL] [Abstract][Full Text] [Related]
5. Role of the S' subsites in serine protease catalysis. Active-site mapping of rat chymotrypsin, rat trypsin, alpha-lytic protease, and cercarial protease from Schistosoma mansoni.
Schellenberger V; Turck CW; Rutter WJ
Biochemistry; 1994 Apr; 33(14):4251-7. PubMed ID: 8155642
[TBL] [Abstract][Full Text] [Related]
6. Secondary substrate binding in aspartic proteinases: contributions of subsites S3 and S'2 to kcat.
Balbaa M; Cunningham A; Hofmann T
Arch Biochem Biophys; 1993 Nov; 306(2):297-303. PubMed ID: 8215428
[TBL] [Abstract][Full Text] [Related]
7. An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.
Skálová T; Hasek J; Dohnálek J; Petroková H; Buchtelová E; Dusková J; Soucek M; Majer P; Uhlíková T; Konvalinka J
J Med Chem; 2003 Apr; 46(9):1636-44. PubMed ID: 12699382
[TBL] [Abstract][Full Text] [Related]
8. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
[TBL] [Abstract][Full Text] [Related]
10. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
[TBL] [Abstract][Full Text] [Related]
11. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity.
Hoog SS; Towler EM; Zhao B; Doyle ML; Debouck C; Abdel-Meguid SS
Biochemistry; 1996 Aug; 35(32):10279-86. PubMed ID: 8756683
[TBL] [Abstract][Full Text] [Related]
14. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
[TBL] [Abstract][Full Text] [Related]
15. Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development.
Beck ZQ; Hervio L; Dawson PE; Elder JH; Madison EL
Virology; 2000 Sep; 274(2):391-401. PubMed ID: 10964781
[TBL] [Abstract][Full Text] [Related]
16. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease.
Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS
Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
Clemente JC; Robbins A; Graña P; Paleo MR; Correa JF; Villaverde MC; Sardina FJ; Govindasamy L; Agbandje-McKenna M; McKenna R; Dunn BM; Sussman F
J Med Chem; 2008 Feb; 51(4):852-60. PubMed ID: 18215016
[TBL] [Abstract][Full Text] [Related]
18. A structural comparison of 21 inhibitor complexes of the aspartic proteinase from Endothia parasitica.
Bailey D; Cooper JB
Protein Sci; 1994 Nov; 3(11):2129-43. PubMed ID: 7703859
[TBL] [Abstract][Full Text] [Related]
19. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.
Sham HL; Zhao C; Stewart KD; Betebenner DA; Lin S; Park CH; Kong XP; Rosenbrook W; Herrin T; Madigan D; Vasavanonda S; Lyons N; Molla A; Saldivar A; Marsh KC; McDonald E; Wideburg NE; Denissen JF; Robins T; Kempf DJ; Plattner JJ; Norbeck DW
J Med Chem; 1996 Jan; 39(2):392-7. PubMed ID: 8558507
[TBL] [Abstract][Full Text] [Related]
20. Reduced-bond tight-binding inhibitors of HIV-1 protease. Fine tuning of the enzyme subsite specificity.
Urban J; Konvalinka J; Stehlíková J; Gregorová E; Majer P; Soucek M; Andreánsky M; Fábry M; Strop P
FEBS Lett; 1992 Feb; 298(1):9-13. PubMed ID: 1544426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
